(Updated - December 22, 2021 3:14 PM EST)

Goldman Sachs analyst Paul Choi lowered the price target on Allakos ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Allakos (ALLK) Climbs After-Hours, Up 13%December 22, 2021 5:37 PM Form 8-K Allakos Inc. For: Dec 21December 22, 2021 11:21 AM BofA Securities Downgrades Allakos Inc. (ALLK) to UnderperformDecember 22, 2021 10:21 AM Pre-Open Stock Movers 12/22: (BRTX) (RCAT) (ACST) (VOYA) Higher, (ALLK) (BABA) Lower (more..) December 22, 2021 8:55 AM Jefferies Downgrades Allakos Inc. (ALLK) to HoldDecember 22, 2021 8:36 AM Allakos (ALLK) Stock Just Crashed 87%. Here's What HappenedDecember 22, 2021 8:27 AM UPDATE: Cowen Downgrades Allakos Inc. (ALLK) to Market PerformDecember 22, 2021 7:39 AM Allakos (ALLK) Resumes Trading Following Halt, Down 88%December 22, 2021 7:14 AM SVB Leerink Downgrades Allakos Inc. (ALLK) to Market PerformDecember 22, 2021 7:02 AM Allakos' (ALLK) Data is Disappointing, Future of lirentelimab is Uncertain - William BlairDecember 22, 2021 6:18 AM UPDATE: William Blair Downgrades Allakos Inc. (ALLK) to Market PerformDecember 22, 2021 6:07 AM Allakos (ALLK) Reports Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal DiseasesDecember 22, 2021 5:39 AM Allakos Inc. (ALLK) PT Lowered to $8 at BarclaysDecember 22, 2021 4:16 AM Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal DiseasesDecember 21, 2021 7:15 PM Allakos Announces Topline Phase 3 Data from the ENIGMA 2 Study and Phase 2/3 Data from the KRYPTOS Study in Patients with Eosinophilic Gastrointestinal DiseasesDecember 21, 2021 7:15 PM